 | • レポートコード：MRC23Q35871 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の慢性疼痛管理薬市場について調査・分析し、世界の慢性疼痛管理薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（オピオイド、非麻薬性鎮痛薬、その他）、用途別セグメント分析（病院、診療所、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer Inc.、Depomed Inc.、Endo International plc.、Purdue Pharma L.P.、Novartis AG、AstraZeneca plc.、Johnson and Johnson Services Inc.、Merck & Co.、Abbott Laboratories、GlaxoSmithKline plc.、Teva Pharmaceutical Industries Ltd.などが含まれています。世界の慢性疼痛管理薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、慢性疼痛管理薬市場規模を推定する際に考慮しました。本レポートは、慢性疼痛管理薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、慢性疼痛管理薬に関するビジネス上の意思決定に役立てることを目的としています。 ・慢性疼痛管理薬市場の概要 - 慢性疼痛管理薬のタイプ別セグメント - 世界の慢性疼痛管理薬市場規模：タイプ別分析（オピオイド、非麻薬性鎮痛薬、その他） - 慢性疼痛管理薬の用途別セグメント - 世界の慢性疼痛管理薬市場規模：用途別分析（病院、診療所、その他） - 世界の慢性疼痛管理薬市場規模予測（2018年-2029年） ・慢性疼痛管理薬市場の成長トレンド - 慢性疼痛管理薬の地域別市場規模（2018年-2029年） - 慢性疼痛管理薬市場ダイナミクス - 慢性疼痛管理薬の業界動向 - 慢性疼痛管理薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：オピオイド、非麻薬性鎮痛薬、その他 - 世界の慢性疼痛管理薬のタイプ別市場規模（2018年-2023年） - 世界の慢性疼痛管理薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、診療所、その他 - 世界の慢性疼痛管理薬の用途別市場規模（2018年-2023年） - 世界の慢性疼痛管理薬の用途別市場規模（2024年-2029年） ・慢性疼痛管理薬の地域別市場規模 - 北米の慢性疼痛管理薬市場規模（2018年-2029年） - アメリカの慢性疼痛管理薬市場規模（2018年-2029年） - ヨーロッパの慢性疼痛管理薬市場規模（2018年-2029年） - アジア太平洋の慢性疼痛管理薬市場規模（2018年-2029年） - 中国の慢性疼痛管理薬市場規模（2018年-2029年） - 日本の慢性疼痛管理薬市場規模（2018年-2029年） - 韓国の慢性疼痛管理薬市場規模（2018年-2029年） - インドの慢性疼痛管理薬市場規模（2018年-2029年） - オーストラリアの慢性疼痛管理薬市場規模（2018年-2029年） - 中南米の慢性疼痛管理薬市場規模（2018年-2029年） - 中東・アフリカの慢性疼痛管理薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer Inc.、Depomed Inc.、Endo International plc.、Purdue Pharma L.P.、Novartis AG、AstraZeneca plc.、Johnson and Johnson Services Inc.、Merck & Co.、Abbott Laboratories、GlaxoSmithKline plc.、Teva Pharmaceutical Industries Ltd. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Chronic Pain Management Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Chronic Pain Management Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Chronic Pain Management Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Chronic Pain Management Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Chronic Pain Management Drugs include Pfizer Inc., Depomed Inc., Endo International plc., Purdue Pharma L.P., Novartis AG, AstraZeneca plc., Johnson and Johnson Services Inc., Merck & Co. and Abbott Laboratories, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chronic Pain Management Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Pain Management Drugs.
The Chronic Pain Management Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Chronic Pain Management Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Pain Management Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer Inc.
Depomed Inc.
Endo International plc.
Purdue Pharma L.P.
Novartis AG
AstraZeneca plc.
Johnson and Johnson Services Inc.
Merck & Co.
Abbott Laboratories
GlaxoSmithKline plc.
Teva Pharmaceutical Industries Ltd.
Segment by Type
Opioids
Non-narcotic Analgesic
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Pain Management Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Pain Management Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Opioids
1.2.3 Non-narcotic Analgesic
1.2.4 Others
1.3 Market by Application
1.3.1 Global Chronic Pain Management Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Pain Management Drugs Market Perspective (2018-2029)
2.2 Chronic Pain Management Drugs Growth Trends by Region
2.2.1 Global Chronic Pain Management Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chronic Pain Management Drugs Historic Market Size by Region (2018-2023)
2.2.3 Chronic Pain Management Drugs Forecasted Market Size by Region (2024-2029)
2.3 Chronic Pain Management Drugs Market Dynamics
2.3.1 Chronic Pain Management Drugs Industry Trends
2.3.2 Chronic Pain Management Drugs Market Drivers
2.3.3 Chronic Pain Management Drugs Market Challenges
2.3.4 Chronic Pain Management Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Pain Management Drugs Players by Revenue
3.1.1 Global Top Chronic Pain Management Drugs Players by Revenue (2018-2023)
3.1.2 Global Chronic Pain Management Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Chronic Pain Management Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Pain Management Drugs Revenue
3.4 Global Chronic Pain Management Drugs Market Concentration Ratio
3.4.1 Global Chronic Pain Management Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Pain Management Drugs Revenue in 2022
3.5 Chronic Pain Management Drugs Key Players Head office and Area Served
3.6 Key Players Chronic Pain Management Drugs Product Solution and Service
3.7 Date of Enter into Chronic Pain Management Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Pain Management Drugs Breakdown Data by Type
4.1 Global Chronic Pain Management Drugs Historic Market Size by Type (2018-2023)
4.2 Global Chronic Pain Management Drugs Forecasted Market Size by Type (2024-2029)
5 Chronic Pain Management Drugs Breakdown Data by Application
5.1 Global Chronic Pain Management Drugs Historic Market Size by Application (2018-2023)
5.2 Global Chronic Pain Management Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Chronic Pain Management Drugs Market Size (2018-2029)
6.2 North America Chronic Pain Management Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Chronic Pain Management Drugs Market Size by Country (2018-2023)
6.4 North America Chronic Pain Management Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Pain Management Drugs Market Size (2018-2029)
7.2 Europe Chronic Pain Management Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Chronic Pain Management Drugs Market Size by Country (2018-2023)
7.4 Europe Chronic Pain Management Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Pain Management Drugs Market Size (2018-2029)
8.2 Asia-Pacific Chronic Pain Management Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Chronic Pain Management Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Chronic Pain Management Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Pain Management Drugs Market Size (2018-2029)
9.2 Latin America Chronic Pain Management Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Chronic Pain Management Drugs Market Size by Country (2018-2023)
9.4 Latin America Chronic Pain Management Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Pain Management Drugs Market Size (2018-2029)
10.2 Middle East & Africa Chronic Pain Management Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Chronic Pain Management Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Chronic Pain Management Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Chronic Pain Management Drugs Introduction
11.1.4 Pfizer Inc. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.1.5 Pfizer Inc. Recent Development
11.2 Depomed Inc.
11.2.1 Depomed Inc. Company Detail
11.2.2 Depomed Inc. Business Overview
11.2.3 Depomed Inc. Chronic Pain Management Drugs Introduction
11.2.4 Depomed Inc. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.2.5 Depomed Inc. Recent Development
11.3 Endo International plc.
11.3.1 Endo International plc. Company Detail
11.3.2 Endo International plc. Business Overview
11.3.3 Endo International plc. Chronic Pain Management Drugs Introduction
11.3.4 Endo International plc. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.3.5 Endo International plc. Recent Development
11.4 Purdue Pharma L.P.
11.4.1 Purdue Pharma L.P. Company Detail
11.4.2 Purdue Pharma L.P. Business Overview
11.4.3 Purdue Pharma L.P. Chronic Pain Management Drugs Introduction
11.4.4 Purdue Pharma L.P. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.4.5 Purdue Pharma L.P. Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Chronic Pain Management Drugs Introduction
11.5.4 Novartis AG Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.5.5 Novartis AG Recent Development
11.6 AstraZeneca plc.
11.6.1 AstraZeneca plc. Company Detail
11.6.2 AstraZeneca plc. Business Overview
11.6.3 AstraZeneca plc. Chronic Pain Management Drugs Introduction
11.6.4 AstraZeneca plc. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.6.5 AstraZeneca plc. Recent Development
11.7 Johnson and Johnson Services Inc.
11.7.1 Johnson and Johnson Services Inc. Company Detail
11.7.2 Johnson and Johnson Services Inc. Business Overview
11.7.3 Johnson and Johnson Services Inc. Chronic Pain Management Drugs Introduction
11.7.4 Johnson and Johnson Services Inc. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.7.5 Johnson and Johnson Services Inc. Recent Development
11.8 Merck & Co.
11.8.1 Merck & Co. Company Detail
11.8.2 Merck & Co. Business Overview
11.8.3 Merck & Co. Chronic Pain Management Drugs Introduction
11.8.4 Merck & Co. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.8.5 Merck & Co. Recent Development
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Company Detail
11.9.2 Abbott Laboratories Business Overview
11.9.3 Abbott Laboratories Chronic Pain Management Drugs Introduction
11.9.4 Abbott Laboratories Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.9.5 Abbott Laboratories Recent Development
11.10 GlaxoSmithKline plc.
11.10.1 GlaxoSmithKline plc. Company Detail
11.10.2 GlaxoSmithKline plc. Business Overview
11.10.3 GlaxoSmithKline plc. Chronic Pain Management Drugs Introduction
11.10.4 GlaxoSmithKline plc. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.10.5 GlaxoSmithKline plc. Recent Development
11.11 Teva Pharmaceutical Industries Ltd.
11.11.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.11.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.11.3 Teva Pharmaceutical Industries Ltd. Chronic Pain Management Drugs Introduction
11.11.4 Teva Pharmaceutical Industries Ltd. Revenue in Chronic Pain Management Drugs Business (2018-2023)
11.11.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details